Relmada Therapeutics (RLMD) EBT Margin (2012 - 2013)
Relmada Therapeutics (RLMD) reported EBT Margin of 776.97% for Q4 2013, down 35724.0% year-over-year from N/an in Q4 2012, and up 74.72% on a QoQ basis from 3073.34% in Q2 2013.
Relmada Therapeutics (RLMD) has 2 years of EBT Margin data on file, last reported at 776.97% in Q4 2013.
- Quarterly EBT Margin fell 35724.0% year-over-year to 776.97% in Q4 2013, while the trailing twelve-month figure through Nov 2013 was 786.85% (changed N/A YoY) and the FY2013 annual result came in at 877.66%, down 72589.0% from the prior year.
- EBT Margin improved to 776.97% in Q4 2013 per RLMD's latest filing, from 3073.34% in the prior quarter.
- Across five years, EBT Margin topped out at 176.73% in Q1 2013 and bottomed at 3073.34% in Q2 2013.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.40% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 41.95% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.05% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 18.99% |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2013 | -776.97% |
| May 31, 2013 | -3,073.34% |
| Feb 28, 2013 | -176.73% |
| Nov 30, 2012 | -419.73% |
| Aug 31, 2012 | -569.57% |
| May 31, 2012 | -620.25% |